EP 0814855 A1 19980107 - FLOW ELECTROPORATION CHAMBER AND METHOD
Title (en)
FLOW ELECTROPORATION CHAMBER AND METHOD
Title (de)
FLUSSELEKTROPORATIONSKAMMER UND VERFAHREN
Title (fr)
CHAMBRE D'ELECTROPORATION EN FLUX ET PROCEDE ASSOCIE
Publication
Application
Priority
- US 9603211 W 19960311
- US 40214595 A 19950310
- US 490695 P 19951006
Abstract (en)
[origin: CA2214800A1] The present invention relates to a method and apparatus for the encapsulatio n of biologically-active substances in red blood cells, characterized by an optionally automated, continuous-flow, self-contained electroporation system (5) which allows withdrawal of blood from a patient, separation of red blood cells, and optional recombination of blood plasma and the modified red blood cells thereby producing blood with modified biological characteristics. The present invention is particularly suited for use to encapsulate allosteric effectors of hemoglobin, thereby reducing the affinity of erythrocytes for oxygen and improving the release of oxygen from erythrocytes in tissues. The blood is introduced into the system (5) at inlet (11) and mixed with an anticoagulant (27). The blood and anticoagulant mixture is passed through a filter (18) and to a blood separation and wash bowl (44). Plasma and white blood cells are admitted into the plasma reservoir (89) while the red blood cells are retained in the wash bowl (44). The separated red blood cells are pumped out and admixed at junction (67) withan IHP solution from reservoir (50). This mixture is cooled by cooling coil (68) and then pumped to electroporation chamber (72) for treatment.
[origin: CA2214800A1] The present invention relates to a method and apparatus for the encapsulation of biologically-active substances in red blood cells, characterized by an optionally automated, continuous-flow, self-contained electroporation system (5) which allows withdrawal of blood from a patient, separation of red blood cells, and optional recombination of blood plasma and the modified red blood cells thereby producing blood with modified biological characteristics. The present invention is particularly suited for use to encapsulate allosteric effectors of hemoglobin, thereby reducing the affinity of erythrocytes for oxygen and improving the release of oxygen from erythrocytes in tissues. The blood is introduced into the system (5) at inlet (11) and mixed with an anticoagulant (27). The blood and anticoagulant mixture is passed through a filter (18) and to a blood separation and wash bowl (44). Plasma and white blood cells are admitted into the plasma reservoir (89) while the red blood cells are retained in the wash bowl (44). The separated red blood cells are pumped out and admixed at junction (67) withan IHP solution from reservoir (50). This mixture is cooled by cooling coil (68) and then pumped to electroporation chamber (72) for treatment.
IPC 1-7
IPC 8 full level
C12N 13/00 (2006.01); A61M 1/36 (2006.01); C12M 3/00 (2006.01)
CPC (source: EP KR US)
A61M 1/3616 (2014.02 - KR); A61M 1/3623 (2022.05 - EP KR US); A61M 1/3687 (2013.01 - EP KR); A61M 1/3692 (2014.02 - EP KR); A61M 1/3693 (2013.01 - KR); C12M 35/02 (2013.01 - EP KR); C12N 13/00 (2013.01 - KR); G05D 23/00 (2013.01 - KR); A61M 1/3616 (2014.02 - EP); A61M 1/3693 (2013.01 - EP); A61M 2202/0429 (2013.01 - EP KR); A61M 2205/3306 (2013.01 - EP KR); A61M 2205/3382 (2013.01 - EP KR); A61M 2205/3606 (2013.01 - EP KR); A61M 2205/3673 (2013.01 - EP KR)
C-Set (source: EP)
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
AU 5305096 A 19961002; CA 2214800 A1 19960919; CA 2214800 C 20020122; CN 1195997 A 19981014; EP 0814855 A1 19980107; EP 0814855 A4 20020717; JP 2007007430 A 20070118; JP 3859709 B2 20061220; JP 4171755 B2 20081029; JP H11502133 A 19990223; KR 19980702848 A 19980805
DOCDB simple family (application)
AU 5305096 A 19960311; CA 2214800 A 19960311; CN 96193177 A 19960311; EP 96909619 A 19960311; JP 2006202504 A 20060725; JP 52774896 A 19960311; KR 19970706255 A 19970908